title: Immunotherapies in clinical trials: do they demand different evaluation tools?
authors.forename: Rabiya S
authors.initials: RS
authors.lastname: Tuma
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D053208:Kaplan-Meier Estimate; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D015233:Models, Statistical; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D014020:Tissue Extracts / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D000074324:Ipilimumab; D014020:Tissue Extracts; C511774:sipuleucel-T; C520704:tremelimumab